The latest announcement is out from Exicure ( (XCUR) ).
Exicure, Inc. has successfully sold its spherical nucleic acid technology and related research to Flashpoint Therapeutics, Inc. for $1.5 million in gross proceeds. The strategic deal enables Exicure to earn future royalties as Flashpoint Therapeutics develops and licenses the acquired assets. This transaction is independent of any other material relationship between the two companies, which negotiated the agreement at arm’s length. Investors are advised that the details of the agreement are specific to the transaction and should not be taken as general information about Exicure’s overall state or prospects.
Find detailed analytics on XCUR stock on TipRanks’ Stock Analysis page.
